Search

everythinglearnresearchcommunity

for

Search:↓

A user took finasteride for six months, then switched to dutasteride for a year, increasing the dosage over time, but hair shedding worsened. Replies suggest the issue is male pattern baldness and DHT-related.

A user is excited to start using Pyriltamide for hair loss after experiencing side effects from topical finasteride. Other users discuss the potential and skepticism of Pyriltamide compared to older treatments like finasteride and RU58841.

The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

Guyman567 has been using oral finasteride and topical minoxidil for years but continues to experience hair loss and thinning, which has affected his confidence. He has tried various treatments including topical finasteride, microneedling, and vitamins, and is considering a hair transplant but is concerned about ongoing hair loss.

The conversation discusses the effectiveness of reducing DHT for hair loss treatment and explores alternative approaches like reducing androgen receptor sensitivity. Specific treatments mentioned include finasteride, dutasteride, pyrilutamide (KX-826), GT20029, and RU58841.

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

A user who has been taking finasteride, minoxidil, and microneedling for one year with no results, and the replies discuss other treatments, including dutasteride, which is feared due to potential side effects.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.

First people receive Pyrilutamide on March 19th, 2022 for hair loss treatment. Users discuss obtaining the drug, its patent, and potential group buys.

The conversation discusses the failure of Phase 3 trials for the hair loss treatment KX-826, with no significant difference found between the drug and placebo. Some users express disappointment and skepticism, while others discuss alternative treatments like Minoxidil, finasteride, and RU58841.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

The user saw no hair regrowth after six months using minoxidil, daily dermarolling, and vitamin D3. Many suggest adding finasteride or dutasteride for better results.

The conclusion of the conversation is that some users have seen positive results with the use of finasteride and minoxidil for hair loss, while others have not. It is mentioned that consistent use of these treatments is necessary to maintain results.

The user is considering switching from finasteride to dutasteride for hair loss. They are unsure if GT20029 can regrow hair, particularly on the temples. Another user mentions that regrowth on finasteride can take up to 2 years.

Pyrilutamide, a potential hair loss treatment that has recently been released for sale, and is thought to have similar efficacy to Dutasteride without side effects. It was discussed in terms of its effectiveness compared to Finasteride, its use by females, and whether it can be safely mixed with RU58841.

A new study suggests microneedling alone doesn't benefit male balding, but users argue the study's methods differ from common practices, like combining microneedling with minoxidil and using more frequent treatments. Some believe the study's short duration and infrequent sessions are inadequate to assess microneedling's effectiveness.

A user shared a six-month update on hair improvement using Pyrilutamide and Minoxidil, noting significant hair regrowth and strength. Some participants questioned the legitimacy of the results and the source of Pyrilutamide.

A user's journey with hair loss and their use of topical finasteride, minoxidil and pyri/minoxidil ratio treatments to attempt hair regrowth. Replies focused on offering support and advice while sharing personal experiences with different treatments.

The conversation is about the safety and effects of using pyrilutamide for hair loss. One person reported severe negative effects, another experienced minor side effects without much benefit for hair, and a third found the anecdote helpful in making a decision.

Kintor's Phase II U.S. trials for pyrilutamide and the process of pharmaceutical drugs coming to market, with a reply from someone who has just ordered 500mg of Pyrilutamide to start their own phase trials.

The conversation discusses skepticism about the effectiveness of new hair loss treatments, mentioning that despite 40 years of research, only accidental discoveries like Minoxidil and Finasteride have been made. It also notes that drug development is a slow process, often taking a decade or more to bring a new drug to market.

Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

The conversation is about a group of people trying KX-826 for hair loss, with no serious side effects reported after 25 days of use. Some participants are experiencing less scalp itch and shedding, but it's too early for definitive results.

The conversation is about experiences with Kintor's KX-826 for hair loss, specifically regarding side effects. Some users reported side effects from grey market versions, questioning their authenticity.

Users discuss aggressive promotion of Koshine 826, suspecting Kintor employees are behind it. Concerns are raised about its effectiveness, with some preferring alternatives like finasteride and minoxidil.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.